NEW YORK, April 10 - Regina Reynolds has been appointed director of marketing and corporate communications at EraGen Biosciences of Madison, Wis., the company said today.
Reynolds joins EraGen from Third Wave Technologies, where she was marketing communications manager for genomic and clinical diagnostics business units. She has also served as marketing communications manager for Smiths Industries Medical Systems and Marketing Services Manager for Schleicher & Schuell, in
Rajen Dalal has been appointed to the board of directors of Ciphergen, the
Dalal is president and CEO of Guava Technologies, which uses mammalian cell profiling and analysis to develop biotechnology drugs. He previously was president of Chiron's blood testing division for ten years, and worked at McKinsey & Company's pharmaceutical and technology management groups. Dalal is a member of the U.S. Department of Health and Human Services' Advisory Committee on Blood Safety and Availability; is also on the board of Sagres Discovery; and is a corporation member of the Bermuda Biological Station for Research.
Richard Gabriel has been appointed president and CEO of DNAPrint Genomics, of
Gabriel comes to DNAPrint from Calix, the owner of pharmaceutical ingredient supplier of Pharm-Eco Laboratories. He has worked for 26 years in the specialty chemical and pharmaceutical industry, according to DNAPrint.
Bernd W. Aundrup, Johann Löhn and Helmut Pende have been nominated to serve on MWG Biotech's supervisory board, the Ebersberg,
The candidates, which will stand for election at the company's annual meeting on May 20, will serve on a three-person external board that supervises the company's operations. Andrup holds a degree in business administration and is a veteran of the pharmaceutical industry. Löhn is Chief Executive Officer of the Steinbeis Foundation for the Promotion of Business and Economy, a backer of technology transfer between academia and industry. Pende has been a member of the Supervisory Board since December 2002.
Denise Gilbert has been nominated for the board of directors of Connectics, a specialty dermatology pharmaceutical company.
Gilbert currently works as an independent consultant. She was CEO of Entigen until 2002, served as CFO and executive vice president of Incyte Pharmaceuticals from 1995 to 1999, and prior to that, was CFO and executive vice president of Affymax.
Roger Salquist has joined the board of directors of Lipomics, of
Salquist is currently on the board of directors of Bay City Capital, where he was the former managing director and a founding partner. Prior to that, Salquist was chairman and CEO of agribusiness company Calgene, which was acquired by Monsanto in 1996.